os pongo esto que he encontrado,a ver si ayuda en algo
Threshold Pharmaceuticals, Inc. (THLD - 7.70) saw a rush of call activity on Monday, after Mizuho Securities started coverage of the stock with a "buy" rating. Close to 9,300 of these options changed hands, which was more than six times above the norm. Most active proved to be the out-of-the-money April 10 strike, where over 7,200 calls were traded -- most of them between the ask and bid prices, making it hard to say with certainty whether they were bought or sold. This strike saw an overnight rise in open interest of 6,160 contracts, pointing to a large influx of new positions. This option now holds peak call open interest of 7,787 contracts.
This preference for calls over puts is hardly unusual for THLD, as the equity sports a 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 3.28. In other words, speculators have bought to open more than three calls for every put during the last two weeks.
However, short interest on the biotech issue skyrocketed by almost 76% during the most recent reporting period, and now accounts for roughly 8% of THLD's available float. This raises the possibility that some of the recent buy-to-open call volume is the result of hedging activity by short sellers.
In terms of technical performance, THLD has gained a staggering 533% year-to-date, and has outpaced the broader S&P 500 Index (SPX) by a whopping 480% during the past 60 days. Back in early February, the stock managed to break free of the $2 mark thanks to a drug-related price surge, and has been trading well above its 20-day moving average ever since. In fact, the equity managed to tag a four-year high of $9.07 on Friday.
At last check, however, THLD is off by more than 7% to hover at $7.70.